Media
View our latest materials to follow our progress in tackling respiratory diseases.
Videos
View all videos
Ensifentrine is an investigational drug and has not been approved by the FDA (or any regulatory authority).
Filters
Verona Pharma to Present Additional Analyses of Positive Phase 3 ENHANCE Studies in COPD at CHEST 2023
PDUFA Target Action Date of June 26, 2024 Pooled analysis and subgroup data further support potential of ensifentrine, an investigational, novel, selective, dual inhibitor of PDE3 and PDE4 LONDON and RALEIGH, N.C., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”
Verona Pharma Announces the US FDA has Accepted the New Drug Application Filing for Ensifentrine for the Maintenance Treatment of COPD
PDUFA Target Action Date of June 26, 2024 Ensifentrine, if approved, is expected to be the first novel mechanism available for the maintenance treatment of COPD in more than a decade
Verona Pharma to Present Additional Analysis of Phase 3 ENHANCE-1 Study in COPD at ERS International Congress 2023
Substantial reductions in rate and risk of exacerbations support potential of ensifentrine, an investigational, novel, selective, dual inhibitor of PDE3 and PDE4
Christina Ackermann Joins Verona Pharma as Non-Executive Director
LONDON and RALEIGH, N.C., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), announces effective September 1, 2023, Ms. Christina Ackermann will join the board as a Non-Executive Director. Ms. Ackermann brings over 25 years of legal and management experience
Verona Pharma Reports Second Quarter 2023 Financial Results and Provides Corporate Update
NDA submitted to US FDA for ensifentrine for maintenance treatment of COPD Phase 3 ENHANCE data published in the American Journal of Respiratory and Critical Care Medicine Strong balance sheet to support commercial launch preparations Conference call today at 9:00 a.m. EDT / 2:00 p.m.
Verona Pharma to Present at 43rd Annual Canaccord Growth Conference
LONDON and RALEIGH, N.C., July 26, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that senior management will present a company overview at the 43rd Annual Canaccord Growth Conference
Verona Pharma
Investor Information
© Verona Pharma plc 2023. All rights reserved